The U.S. Food and Drug Administration (FDA) has officially issued modified risk granted orders (MRTPs) for 20 ZYN nicotine pouch products manufactured by Swedish Match USA. The decision marks a significant milestone for the nicotine pouch category and the broader tobacco harm reduction landscape. 

Under the authorization, the approved ZYN products may now legally be marketed with the following FDA-authorized modified risk claim: 

“Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” 

The authorization follows an extensive scientific review by the FDA and represents one of the clearest examples yet of the agency formally acknowledging the reduced-risk profile of smoke-free nicotine alternatives compared to combustible cigarettes. 

 

Which ZYN Products Received MRTP Authorization? 

 

The modified risk granted orders apply to the following ZYN nicotine pouch flavors, each authorized in both 3mg and 6mg nicotine strengths: 

 

 

• ZYN Chill  
• ZYN Cinnamon  
• ZYN Citrus  
• ZYN Coffee  
• ZYN Cool Mint  
• ZYN Menthol  
• ZYN Peppermint  
• ZYN Smooth  
• ZYN Spearmint  
• ZYN Wintergreen  

 

These products were already authorized for sale through the PMTA pathway in January 2025. The new MRTP authorization now allows Swedish Match to communicate specific reduced-risk information to adult consumers who smoke. 

 

What This Means for the Nicotine Industry 

 

For retailers, distributors, and manufacturers, this decision is a major development. 

The FDA’s MRTP pathway is considered one of the most difficult regulatory hurdles in the tobacco and nicotine industry. To receive authorization, companies must demonstrate not only that the products present lower risks compared to cigarettes, but also that consumers understand the claims and that the products benefit public health overall. 

According to the FDA, Swedish Match successfully demonstrated: 

• The modified risk claim is scientifically accurate  
• Adult consumers understand the claim  
• The products present lower health risks than cigarettes  
• Marketing the products with the claim benefits the population as a whole  
• Youth uptake concerns remain appropriately addressed  

 

This is particularly notable because FDA’s review included data on toxicology, consumer perception, population impact, and youth risk, along with recommendations from the Tobacco Products Scientific Advisory Committee (TPSAC). 

 

A Significant Harm Reduction Milestone 

 

The FDA’s announcement reinforces a growing body of evidence supporting smoke-free nicotine alternatives as lower-risk options for adult smokers who would otherwise continue smoking combustible cigarettes. 

While the agency continues to emphasize that no tobacco product is completely safe, it also acknowledged that completely switching from cigarettes to authorized nicotine pouches can reduce exposure to many harmful chemicals associated with smoking. 

For years, public health discussions around nicotine products have often blurred the line between combustible tobacco and non-combustible alternatives. This authorization signals a continued shift toward recognizing the continuum of risk among nicotine products. 

It also creates a clearer regulatory framework for companies pursuing science-backed reduced-risk claims in the future. 

 

Why the MRTP Pathway Matters 

 

Unlike standard PMTA authorization, which simply permits a product to be sold legally in the United States, the MRTP pathway allows manufacturers to communicate reduced-risk information directly to consumers. 

That distinction is critical. 

Without MRTP authorization, companies are heavily restricted in how they discuss relative risk, even when substantial scientific evidence exists. FDA’s decision effectively acknowledges that adult smokers deserve access to accurate, science-based information when making decisions about potentially lower-risk alternatives. 

The agency also noted that these orders are product-specific and do not automatically apply to all nicotine pouch products or the category as a whole. 

 

Postmarket Requirements and Future Oversight 

 

As part of the authorization, Swedish Match must continue conducting postmarket surveillance and behavioral studies to evaluate: 

• Consumer understanding of the modified risk claim  
• Usage patterns among consumers  
• Population-level impact  
• Potential youth uptake trends  

 

The modified risk orders will expire after five years unless renewed by FDA. 

The agency also stated it retains the authority to withdraw the authorization if future evidence shows the products no longer benefit public health overall. 

 

What Retailers and Distributors Should Watch 

 

This decision could have significant downstream effects across the nicotine pouch market and the broader smoke-free category. 

Key areas to watch include: 

• Increased consumer awareness of nicotine pouches  
• Potential growth in pouch category demand  
• More manufacturers pursuing MRTP applications  
• Expanded conversations around tobacco harm reduction  
• Additional FDA scrutiny on scientific substantiation and youth prevention measures  

For retailers, this may also influence consumer purchasing behavior as adult smokers increasingly seek alternatives positioned around reduced-risk messaging backed by FDA authorization. 

 

Looking Ahead 

 

FDA’s modified risk authorization for 20 ZYN nicotine pouch products represents one of the most consequential nicotine pouch regulatory developments to date. 

While the agency continues to maintain strict oversight of tobacco and nicotine products, today’s decision further establishes that scientifically substantiated harm reduction claims can receive federal authorization when supported by robust evidence. 

For the nicotine industry, it is another sign that the regulatory conversation around smoke-free alternatives continues to evolve—and that evidence-based harm reduction remains an increasingly important part of that discussion.